FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
About
ceo
Mr. Sumit Aggarwal M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.eloxxpharma.comexchange
OTC
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
CIK
0001035354
ISIN
US29014R2022
CUSIP
29014R103
Address
480 Arsenal Way
Phone
781 577 5300
Country
US
Employee
18
IPO Date
Apr 26, 1999
Key Executives
Name
Title
Pay
Year Born
Dr. Ali Hariri M.D.
Chief Medical Officer
0
N/A
Ms. Barbara A. Ryan
Investor Relations Officer
0
1960
Mr. Sumit Aggarwal M.B.A.
President, Chief Executive Officer & Dir...
839.67k
1973
Mr. Daniel E. Geffken M.B.A.
Interim Chief Financial Officer, Princip...
63.96k
1957
As of December 31, 2024, the total employee count stands at 18, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
